Ozlem Goker-Alpan, MD, Founder and CMO of Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), discusses newborn screening for lysosomal disorders.
Newborn screening plays a crucial role in the diagnosis of rare diseases. Waiting for the onset of clinical manifestations can lessen the effects of treatment, making early detection of rare disorders key to better treatment outcomes. Newborn screening can also give researchers and physicians a better understanding of disease progression. This is due to catching the early stages, usually when patients are asymptomatic.
Dr. Goker-Alpan also talks about GRIDS, a symposium focused on informing professionals on lysosomal disorders. The symposium reaches professionals around the world and allows for networking and collaboration opportunities, including the opportunity to talk about newborn screening strategies for lysosomal disorders.
Last year’s GRIDS presentations can be found on our website at https://checkrare.com/learning-center/courses/
Dr. Goker-Alpan’s organization, the LDRTC, is focused on bringing the latest updates in rare lysosomal diseases and their treatments to patients. For more information, visit https://www.lysosomalcenter.org/
For more information on rare lysosomal storage disorders, visit https://checkrare.com/diseases/lysosomal-storage-disorders/